Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 1323495 in Healthy Subjects
NCT04107805Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BI 1323495 in bronchiectasis, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) (9 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Participants With Treatment-emergent Drug-related Adverse Events (AEs) up to 18 days. Started Nov 2019; status: completed.
02
Drugs
BI 1323495
03
Conditions
bronchiectasischronic obstructive pulmonary disease (COPD)cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT04107805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04107805.